44 related articles for article (PubMed ID: 19890040)
1. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
[TBL] [Abstract][Full Text] [Related]
2. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
3. A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins.
Garcia BL; Summers BJ; Ramyar KX; Tzekou A; Lin Z; Ricklin D; Lambris JD; Laity JH; Geisbrecht BV
J Biol Chem; 2013 Jan; 288(4):2870-81. PubMed ID: 23233676
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of complement inhibition by a mosquito protein revealed through cryo-EM.
Andersen JF; Lei H; Strayer EC; Pham V; Ribeiro JMC
Commun Biol; 2024 May; 7(1):649. PubMed ID: 38802531
[TBL] [Abstract][Full Text] [Related]
5. Quantification of the zymogenicity and the substrate-induced activity enhancement of complement factor D.
Dani R; Oroszlán G; Martinusz R; Farkas B; Dobos B; Vadas E; Závodszky P; Gál P; Dobó J
Front Immunol; 2023; 14():1197023. PubMed ID: 37283768
[TBL] [Abstract][Full Text] [Related]
6. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
[TBL] [Abstract][Full Text] [Related]
7. Modeling C3 glomerulopathies: C3 convertase regulation on an extracellular matrix surface.
Pisarenka S; Meyer NC; Xiao X; Goodfellow R; Nester CM; Zhang Y; Smith RJH
Front Immunol; 2022; 13():1073802. PubMed ID: 36846022
[TBL] [Abstract][Full Text] [Related]
8. Nanometer- and angstrom-scale characteristics that modulate complement responses to nanoparticles.
Moghimi SM; Haroon HB; Yaghmur A; Simberg D; Trohopoulos PN
J Control Release; 2022 Nov; 351():432-443. PubMed ID: 36152807
[TBL] [Abstract][Full Text] [Related]
9. Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.
Bansal L; Nichols EM; Howsmon DP; Neisen J; Bessant CM; Cunningham F; Petit-Frere S; Ludbrook S; Damian V
Front Pharmacol; 2022; 13():855743. PubMed ID: 35517827
[No Abstract] [Full Text] [Related]
10. C3(H2O) prevents rescue of complement-mediated C3 glomerulopathy in Cfh-/- Cfd-/- mice.
Zhang Y; Keenan A; Dai DF; May KS; Anderson EE; Lindorfer MA; Henrich JB; Pitcher GR; Taylor RP; Smith RJ
JCI Insight; 2020 May; 5(9):. PubMed ID: 32376801
[TBL] [Abstract][Full Text] [Related]
11. Mathematical Modelling of Alternative Pathway of Complement System.
Bakshi S; Cunningham F; Nichols EM; Biedzka-Sarek M; Neisen J; Petit-Frere S; Bessant C; Bansal L; Peletier LA; Zamuner S; van der Graaf PH
Bull Math Biol; 2020 Feb; 82(2):33. PubMed ID: 32062771
[TBL] [Abstract][Full Text] [Related]
12. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.
Dobó J; Kocsis A; Gál P
Front Immunol; 2018; 9():1851. PubMed ID: 30135690
[TBL] [Abstract][Full Text] [Related]
13. The Sand Fly Salivary Protein Lufaxin Inhibits the Early Steps of the Alternative Pathway of Complement by Direct Binding to the Proconvertase C3b-B.
Mendes-Sousa AF; do Vale VF; Silva NCS; Guimaraes-Costa AB; Pereira MH; Sant'Anna MRV; Oliveira F; Kamhawi S; Ribeiro JMC; Andersen JF; Valenzuela JG; Araujo RN
Front Immunol; 2017; 8():1065. PubMed ID: 28912782
[TBL] [Abstract][Full Text] [Related]
14. Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.
Ricklin D; Reis ES; Mastellos DC; Gros P; Lambris JD
Immunol Rev; 2016 Nov; 274(1):33-58. PubMed ID: 27782325
[TBL] [Abstract][Full Text] [Related]
15. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
16. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.
Chauvet S; Roumenina LT; Bruneau S; Marinozzi MC; Rybkine T; Schramm EC; Java A; Atkinson JP; Aldigier JC; Bridoux F; Touchard G; Fremeaux-Bacchi V
J Am Soc Nephrol; 2016 Jun; 27(6):1665-77. PubMed ID: 26471127
[TBL] [Abstract][Full Text] [Related]
17. Complement System Part I - Molecular Mechanisms of Activation and Regulation.
Merle NS; Church SE; Fremeaux-Bacchi V; Roumenina LT
Front Immunol; 2015; 6():262. PubMed ID: 26082779
[TBL] [Abstract][Full Text] [Related]
18. Putting the structure into complement.
Lea SM; Johnson S
Immunobiology; 2012 Nov; 217(11):1117-21. PubMed ID: 22964238
[TBL] [Abstract][Full Text] [Related]
19. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function.
Roumenina LT; Frimat M; Miller EC; Provot F; Dragon-Durey MA; Bordereau P; Bigot S; Hue C; Satchell SC; Mathieson PW; Mousson C; Noel C; Sautes-Fridman C; Halbwachs-Mecarelli L; Atkinson JP; Lionet A; Fremeaux-Bacchi V
Blood; 2012 May; 119(18):4182-91. PubMed ID: 22246034
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
